Özen 1998.

Methods	Methodological quality Generation of allocation sequence: described as randomised (unclear). Allocation concealment: unclear. Double blinding: no or inadequate methods of blinding (unclear). Follow‐up: not reported (unclear).
Participants	Inclusion criteria of patients HBeAg and HBV DNA positive, ALT levels > 40IU/L, Chronic hepatitis. Exclusion criteria of patients Previously antiviral therapy, lekopenia, thrombocytopenia, elevated serum creatinine level, cirrhosis, other causes of liver disease or malignancy. Characteristics of included patients Gluco+IFN ‐ 13 patients Age: 8.4 male/female: 11/2 Mean ALT: 177.6 Control+IFN ‐ 16 patients Age: 8.2 years male/female: 13/3 Mean ALT: 175.3.
Interventions	Gluco+IFN: 3 weeks of prednisone 60 mg/day with 1 week tapering followed by 24 weeks of IFN 5 MU/sqm thrice weekly. Total prednisone dose: 1260 mg. Control+IFN: 24 weeks of IFN 5 MU/sqm thrice weekly. Total IFN dose: 331 MU.
Outcomes	Loss of HBeAg, loss of HBV DNA, anti‐HBe positivity, ALT levels. Follow‐up period: 6 months after the end of treatment.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear